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INTRODUCTION:
OBSTACLES TO THE DEVELOPMENT
AND USE OF PHARMACOTHERAPIES
FOR ADDICTION
RICHARD C. BOLDT*

More than a decade ago, Dr. Alan Leshner, then the Director of the National
Institute on Drug Abuse, undertook a campaign in which he and other leaders in the
addictions field sought to educate policy makers and the public generally about the
significant neurophysiological components of drug use disorders. Oversimplifying,
as public policy campaigns often do, Leshner asserted that "addiction is a brain
disease."1 In fact, as Professor Richard J. Bonnie explained in his Stuart Rome
Lecture, delivered on November 7, 2008 as part of a Symposium organized by the
University of Maryland School of Law's Law & Health Care Program on Obstacles
for Addiction, alcohol and other
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components, which Bonnie characterized as "substantial,, 3 are important because
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Although the initial use of alcohol or other drugs often is voluntary, the
continued ingestion of some of these substances can lead to physical dependency.
An individual who is physically dependent may experience tolerance, which is the
need for increasing amounts of the drug in order to achieve a consistent effect, and
may suffer physical symptoms of withdrawal if administration of the drug is
suspended.5 Most diagnostic schemes require symptoms beyond tolerance and
Copyright © 2010 by Richard C. Boldt.
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1. Alan I. Leshner, Addiction Is a Brain Disease, and It Matters, 278 SCL 45 (1997).
2. Richard J. Bonnie, The Virtues of Pragmatism in DrugPolicy, 13 J. HEALTH CARE L. & POL'Y
7, 20 (2010).
3. Indeed, Professor Bonnie suggested that the behavioral and contextual components of addiction
are "much more substantial . . . than in Alzheimer's disease, Parkinson disease, epilepsy, or
schizophrenia." Id.
4. Id. at 22.
5. A. Thomas McLellan et al., Drug Dependence, A Chronic Medical Illness: Implicationsfor
Treatment, Insurance,and Outcomes Evaluation, 284 JAMA 1689, 1690-91 (2000); see also Editorial,
Symptoms in Chronic Morphinism Induced by Withdrawal of the Drug, 62 JAMA 1662, 1663 (1914)
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withdrawal, however, in order for a substance use disorder diagnosis to be made.
These additional symptoms, particularly relating to the presence of a persistent
desire or craving for the substance, its continued use despite substantial social,
legal, or physical costs, and the like, also have a neurobiological basis. This is
because the continued heavy use of alcohol and other drugs brings about significant
structural changes in areas of the brain that are critical to judgment, learning, and
behavior control. 7 As Professor Bonnie explained, "due to neurobiological
processes deep in the brain over which the addict no longer has any control, he is
experiencing a strong need for or desire for substance, and.., this need is so great
that it is unlikely that he will be able to resist it." 8 The difficulty for policy makers,
however, is that these cravings are operationalized through the decision-making
machinery that ordinarily marks individuals as responsible agents.
Mindful that drug use disorders are complex phenomena that involve
physiological, environmental, and behavioral elements, Professor Bonnie used the
occasion of his Rome Lecture to urge a middle position between, on the one hand,
understanding addiction solely as willful misconduct, 9 and, on the other, conceiving
of it as entirely beyond the reach of the criminal enforcement system. Instead, he
urged the development of a "stable, and essentially pragmatic, drug policy that
avoids the ideologically driven positions that have for so long dominated policy
discourse .... "10 Such a pragmatic policy, he explained, would serve to increase
the use of those medications that are already available to treat drug use disorders,
and, in the process, encourage the development of new pharmacotherapies for
addiction. 1
Clinicians have long understood that alcohol and other drug use disorders are
chronic relapsing conditions, and that relapse has both biological and behavioral
features.12 In light of this understanding, a number of experts have urged the
development of a comprehensive treatment system to provide care across a variety

("The sudden withdrawal of [morphine] does not result merely in negative symptoms, but often
produces such intense misery and depression as to indicate actual danger.").
6. McLellan et al., supra note 5, at 1690.
A

7. PHYSICIANS & LAWYERS FOR NAT'L DRUG POLICY, ALCOHOL AND OTHER DRUG PROBLEMS:
PUBLIC
HEALTH
AND
PUBLIC
SAFETY
PRIORITY
14
(2008),
available at

http://wwwl .spa.american.edu/justice/document.php?ID=2434.
8. Bonnie, supra note 2, at 22. The sustained use of alcohol and other drugs over time alters the
way that neurons communicate. PHYSICIANS & LAWYERS FOR NAT'L DRUG POLICY, supra note 7, at 14.

Some drugs activate neurons by "mimicking" the properties of naturally occurring neural transmitters,
while others function to block neural transmitters by, for example, blocking the substances that normally
clear the synapses or spaces between neurons. Id.
9. See Traynor v. Turnage, 485 U.S. 535, 552 (1988) (rejecting a challenge to the characterization
by the Department of Veterans Affairs of primary alcoholism as "willful misconduct").
10. Bonnie, supra note 2, at 7.
11. Id. at 30.
12. Leshner, supra note 1, at 45.
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of levels and through a range of different treatment modalities. Importantly, this
sort of comprehensive approach to substance abuse treatment would include both
behavioral and pharmacological interventions. 13 As things now stand, the range of
treatment options available to those in need often is neither comprehensive nor
readily available. Although medications are used regularly during the detoxification
phase of substance abuse treatment to manage the physical symptoms of tolerance
and withdrawal, 14 there has been resistance among some treatment providers,
policy makers, actors within the legal system, and others to the further use of
pharmacotherapies to manage drug craving and maintain patients in recovery. This
resistance has been fueled, in part, by a perspective that emphasizes the behavioral
and contextual features of addiction, and that defines recovery as freedom from all
drug dependency.' 5
Available medications for the treatment of opioid dependency include
methadone, a synthetic opioid that functions as an "agonist" to activate receptors in
the brain in order to limit the effect of heroin and prescription opioids;
buprenorphine, a partial agonist also used in the treatment of opioid addiction; and
naltrexone, an opioid "antagonist," that blocks receptors in the brain so as to
16
prevent users from obtaining the euphoric effects of heroin and other opioids.
Methadone can be used as a short-term therapy or in a long-term maintenance
regime. Used alone, methadone treatment is not a cure for opioid addiction, but the
evidence clearly demonstrates that it is effective in improving treatment retention,
decreasing relapse, and ameliorating the other social, legal, and medical problems
often associated with illicit drug misuse. 17 Methadone treatment is provided in
specialized treatment facilities that are closely regulated and monitored by the
federal government. Buprenorphine, by contrast, is available by prescription from
primary care physicians and other physicians in more decentralized clinical
settings. Prescribing doctors need not be addiction medicine specialists, although
they must receive some specialized training and are subject to restrictions on the
8
number of patients they can treat.'

13. McLellan et al., supra note 5, at 1693. The National Institute on Drug Abuse has developed a
set of principles governing the effective treatment of addiction for persons in the criminal justice system.
NAT'L INST. OF DRUG ABUSE, NAT'L INSTS. OF HEALTH, NIH PUB. NO. 06-5316, PRINCIPLES OF DRUG
ABUSE TREATMENT FOR CRIMINAL JUSTICE POPULATIONS: A RESEARCH-BASED GUIDE 1-5 (2007),

available at http://www.nida.nih.gov/PDF/PODAT CJ/PODATCJ.pdf. Among the principles is that
"[m]edications are an important part of treatment for many drug abusing offenders." Id. at 5.
14. PHYSICIANS & LAWYERS FOR NAT'L DRUG POLICY, supra note 7, at 35.
15. Id.
at 36.
16. Id.
at 40-41.
17. Karen L. Sees et al., Methadone Maintenance vs 180-Day Psychosocially Enriched
Detoxificationfor Treatment of Opioid Dependence:A Randomized Controlled Trial, 283 JAMA 1303,
1309 (2000).
18. PHYSICIANS & LAWYERS FOR NAT'L DRUG POLICY, supra note 7, at 41.
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As brain science has improved, potential new therapies, including new
medications to assist in the management of drug craving reactions and to respond to
the problem of relapse, are on the developmental horizon.' 9 Unfortunately,
obstacles exist at each stage of the process by which new medications are
developed, tested, approved, and distributed, to limit the availability and use of
potentially effective pharmacotherapies, either alone or in conjunction with other
modalities of treatment. Panelists at the November 7, 2008 Law & Health Care
Program Symposium explored the impediments at each of these stages including
those bearing on the decision making of the pharmaceuticals industry, the FDA
approval process, and clinical trials. In addition, speakers took up the question of
insurance obstacles and the reluctance of physicians to prescribe medications for
addiction, and a special panel was devoted to the unwillingness of many decision
makers within the criminal justice system to order the use of methadone
maintenance therapy and other pharmacotherapies.
In addition to Professor Bonnie's Rome Lecture, two additional papers from
the Symposium are included in this issue of the Journal of Health Care Law &
Policy. The article by Professor James L. Nolan, Jr.,20 draws upon ethnographic
material he collected in preparing his recent book on problem-solving courts in the
U.S., Scotland, Ireland, Canada, Australia, and England. 21 Nolan reports that drug
courts in each of the jurisdictions that he studied, other than the United States, rely
on methadone maintenance as a "main staple" of the drug abuse treatment they
provide.22 In the United States, by contrast, the majority of drug courts do not make
use of methadone maintenance treatment or other pharmacotherapies. 23 In the case
of the U.K., Nolan explains, the reliance on methadone and other
pharmacotherapies is due to Britain's longstanding practice of according a leading
role to physicians in the setting of drug policy and is consistent with the tradition of
English doctors providing maintenance drugs for "stable addicts., 24 More broadly,
he suggests that the different disposition toward the use of medications to manage
addictions is due to a fundamental difference of perspective between those who
direct drug courts in the U.S. and elsewhere. "The goal of most U.S. drug courts is
'total abstinence,' or what some have referred to as 'demand reduction.'- 2 5 In all of

19. See Medications Development at NIDA, TOPICS IN BRIEF (Nat'l Inst. on Drug Abuse, Nat'l
Insts. of Health), July 2008, available at http://www.nida.nih.gov/pdf/tib/MedicationsDev.pdf
(discussing research efforts at the National Institute on Drug Abuse to develop new addiction
medications).
20. James L. Nolan, Jr., Harm Reduction and the American Difference: Drug Treatment and
Problem-SolvingCourts in ComparativePerspective, 13 J. HEALTH CARE L. & POL'Y 31 (2010).
21. JAMES L. NOLAN JR., LEGAL ACCENTS, LEGAL BORROWING: THE INTERNATIONAL PROBLEM-

SOLVING COURT MOVEMENT (2009).
22. Nolan, supra note 20, at 39.
23. Id. at 36-37.
24. Id. at 39-40.
25. Id. at 36.

2010]

INTRODUCTION

the other jurisdictions he examined, Nolan reports that the abstinence model has
given way to a harm minimization approach. Under this approach the goals of the
program are defined in terms of the reduced use of substances of abuse and reduced
criminal offending, and treatment interventions are selected accordingly.26
The article by Professor Ellen Weber 27 focuses on the failure of physicians in
the United States to prescribe pharmacotherapies for the treatment of alcohol and
other drug use disorders. Professor Weber asserts that this failure "goes to the heart
of our nation's failed drug policies. 28 She catalogues the different reasons for the
underutilization of medication-based therapies in the treatment of alcoholism and
opioid dependence, stressing inadequacies in the medical training that physicians
receive, the persistent stigma associated with those who suffer from addictions
disorders, and the compensation barriers to the provision of effective treatment.29
Professor Weber also discusses the tradition in the U.S. of providing alcohol and
other drug abuse treatment services outside of primary care settings. 30 This failure
to mainstream addictions diagnosis and treatment, which is exemplified by the
highly segregated setting within which methadone treatment is made available, has
served as an obstacle to the development of new therapies and has contributed to
the underutilization of those medications that are available. "Succinctly stated,"
states Professor Weber, "four interrelated factors---context, competence, comfort,
and compensation-affect physician prescription practices in the United States."3 1
The abuse of alcohol and other drugs is a serious health problem throughout
the United States. An estimated 22.6 million Americans abuse alcohol and other
drugs on a regular basis.32 The costs to individuals, families, and communities are
enormous. 33 Neuroscientists have learned a great deal about how alcohol and other
drugs of abuse work to "produce pleasure by activating a specific network of
neurons called the brain reward system., 34 Researchers have also gained new
insights into how neurophysiology interacts with genetic susceptibility and
environmental factors in the case of individuals with drug use disorders.35 Given
this understanding, it is clear that the use of medications-those already available
and new pharmacotherapies that are only on the bench or in clinical trial-must be

26. Id. at 36, 38.
27. Ellen M. Weber, Failure of Physicians to Prescribe Pharmacotherapiesfor Addiction:

Regulatory Restrictions and Physician Resistance, 13 J. HEALTH CARE L. & POL'Y 49 (2010).
28. Id. at 51.
29. Id. at 69-75.
30. Id. at 55-66.
31. Id. at 51.
32. PHYSICIANS & LAWYERS FOR NAT'L DRUG POLICY, supra note 7, at 9.

33. Id. at 12.
34. SOC'Y FOR NEUROSCIENCE, BRAIN FACTS: A PRIMER ON THE BRAIN AND NERVOUS SYSTEM 36

(2008), availableat http://www.sfi.org/skins/main/pdf/brainfacts/2008/brain-facts.pdf.
35. Id. at 37.
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included in any effective and comprehensive response to this public health
problem.

